Texas NeuroAIDS Research Center

德克萨斯神经艾滋病研究中心

• 批准号: 10818807
• 负责人: BENJAMIN B. GELMAN
• 金额: $ 21.68万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10818807
• 关键词: Autopsy; Biological Assay; Biological Specimen Banks; Blood; Brain; Budgets; Cerebrospinal Fluid; Client; Clinic; Clinical; Clinical Data; Communication; Communities; Contracts; Data; Data Collection; Data Coordinating Center; Discipline of Nursing; Disparity population; Economically Deprived Population; Elderly; Equilibrium; Equipment; Equipment and supply inventories; Funding; Future; HIV; HIV Seropositivity; HIV/AIDS; Human; Institutional Review Boards; Maintenance; Measures; Medical; National NeuroAids Tissue Consortium; Nervous System; Neuropsychology; Notification; Nursing Staff; Patients; Population; Procedures; Process; Repository Operations; Research; Research Personnel; Resources; Safety; Schedule; Services; Site; Source; Specimen; Substance abuse problem; Supervision; Texas; Time; Toxicology; Transportation; Travel; U-Series Cooperative Agreements; United States National Institutes of Health; Visit; Writing; clinical database; clinical research site; cost; human tissue; medical schools; neuroAIDS; operation; opioid overdose; professor; programs; quality assurance; recruit; social disparities; substance use; virology

Abstract This application is for supplemental bridge funding to maintain operation of the Texas NeuroAIDS Research Center (TNRC) for a brief period of time (U24MH10093010). This project recruits HIV positive patients, characterizes them medically and neuropsychologically, performs autopsies when appropriate, maintains a human specimen repository, and distributes specimens worldwide. The funding for fiscal year 5 of this cooperative agreement U24 was to end on February 28, 2023. As of this writing the program is operating on a no cost extension combined with a pending request for “carry forward” funds from prior years that has not yet been approved. The application for continued funding via contracting is under a review by the NIH. According to federal officials the decision regarding funding in the future will not be known for approximately six months from the end of the U24. That has created a “funding gap.” Following the advice of federal officials, we are applying for supplemental bridge funding to maintain normal operations until a decision on long term funds is issued by the NIH. We were advised to apply for funds that will allow operation through August 31, 2023, which amounts to roughly six months of normal operation from the time the U24 was to end. Our request for bridge funds for that period is calculated in a manner suggested by the NIH. We have subtracted from our request two sources of potentially available funds: 1) the balance that was available for an approved no cost extension, and 2) a separate amount corresponding to a pending request for carry forward of unspent funds from prior years. Assuming that these two requests are both approved and enacted by the NIH, we calculated an amount of additional funds necessary to operate through September 1, 2023. That amount is reflected in our budget request and its justification. Supplemental funding is requested to maintain operation until the long-term plan for funding the project become clear.

抽象的 此申请用于补充过桥资金，以维持德克萨斯州 NeuroAIDS 的运作 研究中心 (TNRC) 短期招募 (U24MH10093010) 该项目招募艾滋病毒阳性者。 患者，从医学和神经心理学上描述他们的特征，在以下情况下进行尸检： 适当的，维护一个人类样本库，并在世界范围内分发样本。 U24 合作协议第 5 财年的资助将于 2023 年 2 月 28 日结束。 编写程序是在免费扩展和待处理的“携带”请求的基础上运行的 前几年尚未批准的继续资助申请。 据联邦官员称，有关资助的决定正在接受美国国立卫生研究院 (NIH) 的审查。 未来的情况将在U24结束后大约六个月内不得而知。 根据联邦官员的建议，我们正在申请补充桥梁。 在 NIH 发布长期资金决定之前，我们将提供维持正常运作的资金。 建议申请资金以允许运营至 2023 年 8 月 31 日，相当于 从我们要求过桥资金开始，大约有六个月的正常运作。 我们已从我们的请求中扣除了该期限的计算方式。 潜在可用资金的两个来源： 1) 可用于批准的免费资金的余额 延期，以及 2) 与未支出结转请求相对应的单独金额 假设这两项请求都得到 NIH 的批准和颁布， 我们需要一定数量的额外资金来运营至 2023 年 9 月 1 日。 金额已反映在我们的预算请求中，并要求提供补充资金。 维持运营，直至项目融资的长期计划明确为止。

项目成果

Lipocalin-2 mediates HIV-1 induced neuronal injury and behavioral deficits by overriding CCR5-dependent protection.

Lipocalin-2 通过超越 CCR5 依赖性保护来介导 HIV-1 诱导的神经元损伤和行为缺陷。

• 发表时间: 2020
• 作者: Ojeda;Shah, Rohan;Fields, Jerel Adam;Harahap;Koury, Jeffrey;Maung, Ricky;Gelman, Benjamin B;Baaten, Bas J;Roberts, Amanda J;Kaul, Marcus
• 通讯作者: Kaul, Marcus

Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered.

抑制性抗逆转录病毒治疗的手部神经病理学：脑炎和神经退行性疾病的重新考虑。

• 发表时间: 2015-06
• 影响因子: 4.6
• 作者: Gelman; Benjamin B
• 通讯作者: Benjamin B

Imaging findings in the progression of a giant cell glioblastoma.

巨细胞胶质母细胞瘤进展的影像学发现。

• 发表时间: 2018-10
• 作者: Turner, Ryan;Matthys, Samuel;Heymann, John;Gelman, Benjamin
• 通讯作者: Gelman, Benjamin

Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.

结构引导药物设计确定了一种 BRD4 选择性小分子，可抑制 HIV。

• DOI: 10.1172/jci120633
• 发表时间: 2019-07-22
• 期刊: The Journal of clinical investigation
• 作者: Q. Niu;Zhiqing Liu;Edrous Alamer;Xiuzhen Fan;Haiying Chen;J. Endsley;B. Gelman;B. Tian;Jerome H. Kim;N. Michael;M. Robb;J. Ananworanich;Jia Zhou;Haitao Hu
• 通讯作者: Haitao Hu

Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1.

感染 HIV-1 的人源化小鼠的肺结核。

• 发表时间: 2016-02-24
• 影响因子: 4.6
• 作者: Nusbaum, Rebecca J;Calderon, Veronica E;Huante, Matthew B;Sutjita, Putri;Vijayakumar, Sudhamathi;Lancaster, Katrina L;Hunter, Robert L;Actor, Jeffrey K;Cirillo, Jeffrey D;Aronson, Judith;Gelman, Benjamin B;Lisinicchia, Joshua G;Valbuena, Gusta
• 通讯作者: Valbuena, Gusta